Catalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for ATI-052 in Asthma, Atopic dermatitis. The expected timing is based on the latest available company guidance and may change.
4/22/25- Received IND clearance. 6/23/25- Ph1a (SAD/MAD)/Ph1b (POC) trials initiated. Complete Ph1a portion by YE 2025 w/ topline results in early 2026. Ph1b portion topline results in H2 2026. 11/06/25:- Plan Ph1b asthma & AD POC study in H1 2026 & reiterated topline data H2 2026. Ph1a SAD dosing complete, MAD dosing ongoing; reiterates early 2026 topline and H2 2026 Ph1b POC results. 01/06/26:- Positive Ph1a SAD/MAD interim data; Ph1b AD/asthma to start Q1 2026, topline and Ph2b AD H2 2026. 01/12/26:- Initiated Ph1b AD POC trial; asthma Ph1b POC starts Q1 2026; topline both H2 2026. 02/24/26:- Initiated Ph1b asthma POC trial; reiterates H2 2026 topline and plans Ph2b asthma/AD program H2 2026. 02/26/26:- Positive Ph1a SAD/MAD interim data; complete results Q2 2026. Ph1b AD/asthma topline and Ph2b start H2 2026. 04/28/26:- Full Ph1a SAD/MAD topline results positive. Ph1b asthma/AD topline expected H2 2026; Phase 2b planned Q4 2026. 05/07/26:- Full Ph1a SAD/MAD data showed best-in-class PK/PD; Ph1b POC topline H2 2026; Ph2b asthma Q4 2026. 08/06/26:- Ph1b AD/asthma data H2 2026; Ph2b asthma Q4 2026; AD/EoE startup planned.
Verification
Confirm timing and program details against the company announcement or filing.